Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients: An 18 to 34-week, open-label, extension period

Diabetes and Metabolism

Volumn 35, Issue 1, 2009, Pages 64-70

  Moulin, P ^a   Andre M ^b   Alawi, H ^c   Dos Santos, L C ^d   Khalid, A K ^e   Koev, D ^f   Moore, R ^g   Serban, V ^h   Picandet, B ^b   Francillard, M ^b  

^a UNIVERSITÉ LYON 1   (France)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^f UNIVERSITY OF SOFIA   (Bulgaria)

^g Umhlanga Hospital   (South Africa)

^h Spitalul Judetean   (Romania)

Author keywords

Benfluorex; HbA1c; LDL cholesterol; Sulfonylurea; Type 2 diabetes

Indexed keywords

ACARBOSE; BENFLUOREX; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FENFLURAMINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; SAFETY; SEROTONIN UPTAKE INHIBITORS; SULFONYLUREA COMPOUNDS; YOUNG ADULT;

EID: 60749111734     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2008.10.002     Document Type: Article

References (21)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabetes 27 (2004) 1047-1053
2. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
3. The ADVANCE Collaborative Group. Intensive blood glucose and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
4. European Diabetes Policy Group 1999. A desktop guide to type 2 diabetes mellitus. Diabet Med 16 (1999) 716-730
5. Nathan D.M., Buse J.B., Davidson M.B., Heine R.J., Holman R.R., Sherwin R., et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustement of therapy. Diabetes Care 29 (2006) 1963-1972
6. Agence française de sécurité sanitaire des produits de santé (Afssaps); Haute Autorité de santé (HAS). Medical treatment of diabetes type 2 - Recommendation for good practice. Diabetes Metab 33 (2007) S7-S25
7. Kohl C., Ravel D., Girard J., and Pegorier J.P. Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression. Diabetes 51 (2002) 2363-2368
8. Bianchi R., Bongers V., Bravenboer B., and Erkelens D.W. Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care 16 (1993) 557-559
9. De Feo P., Lavielle R., De Gregoris P., and Bolli G.B. Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus. Diabetes Metab Rev 9 Suppl.1 (1993) 35S-41S
10. Riccio A., Vigili de Kreutzenberg S., Dorella M., Da Tos V., De Biasi L., Marescotti M.C., et al. Mechanism(s) of the blood glucose lowering action of benfluorex. Diabetes Metab Rev 9 (1993) 19S-27S
11. Del Prato S., Erkelens D.W., and Leutenegger M. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol 44 (2003) 20-27
12. Moulin P., Andre M., Alawi H., Dos Santos L.C., Khalid A.K., Koev D., et al. Efficacy of benfluorex in combination with sulfonylurea in type 2 diabetic patients. Diabetes Care 29 (2006) 515-520
13. Howlett H.C., and Bailey C.J. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf 20 (1999) 489-503
14. Cockcroft D.W., and Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976) 31-41
15. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
16. The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use. London 30 May 2002. CPMP/EWP/1080/00 2002.
17. NCEP adult treatment panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-97.
18. Stucci N., De Gregoris P., Lavielle R., and Tomasi F. Therapeutic benefit of benfluorex in type II diabetic patients treated with sulfonylureas. J Diabetes Complications 10 (1996) 267-273
19. Nathan D.M. Finding new treatments for diabetes. How many, how fast ... how good?. N Engl J Med 356 (2007) 437-439
20. Bolen S., Feldman L., Vassy J., Wilson L., Yeh H.C., Marinopoulos S., et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147 (2007) 386-399
21. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554